U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07055880) titled 'Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)' on May 23.
Brief Summary: To describe the immunogenicity and safety of two dosages of Sinovac rabies vaccine, as well as compared the differences with the marked WHO PQ rabies vaccine Verorab(R) in a post-exposure prophylaxis (PEP) schedule.
Study Start Date: July 28
Study Type: INTERVENTIONAL
Condition:
Rabies
Intervention:
BIOLOGICAL: Rabies Vaccine (Serum-free Vero Cell), Freeze-dried
Receiving five doses of rabies vaccine manufactured by Sinovac using the "Essen" PEP schedule
BIOLOGICAL: Verorab(R)
Receiving five doses of marketed r...